Seborrheic dermatitis

Topical Metronidazole Therapeutic Cheat Sheet
topical metronidazoleMetronidazole is a nitroimidazole with antiprotozoal, antibacterial, and anti-inflammatory properties and is available in oral and topical formulations. The diverse mechanisms of action of metronidazole have expanded its utility across various dermatologic conditions. Topical metronidazole is well tolerated and has demonstrated improvements in inflammatory papules and pustules of rosacea. We conti …
topical metronidazole
Ciclopirox Therapeutic Cheat Sheet
CiclopiroxCiclopirox is the only hydroxypyridone antifungal agent with a unique mechanism of action differentiating it from other antimycotic agents. Unlike the azole-antifungals which block the sterol synthesis in the fungal cell membrane, ciclopirox functions by chelating cations resulting in the degradation of fungal cells, as well as proposed anti-inflammatory properties. It is available in a variety of …
Ciclopirox
Navigating the Complexities of Alopecia: Insights from Dr. Adam Friedman
alopeciasDr. Adam Friedman's lecture at 2024 ODAC conference provided invaluable insights into the nuanced approach required when dealing with patients presenting with alopecia. Addressing the diverse array of alopecia types and their myriad presentations, Dr. Friedman emphasized the significance of a comprehensive clinical history and evaluation to formulate an effective treatment plan. By employing a cas …
alopecias
Topical Ruxolitinib Therapeutic Cheat Sheet
RuxolitinibRuxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT …
Ruxolitinib
Roflumilast Therapeutic Cheat Sheet
RoflumilastRoflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o …
Roflumilast